Oxaliplatin Accord

Oxaliplatin, the active ingredient in Oxaliplatin Accord, is a platinum‑based chemotherapy presented as a strength/form for intravenous use. It treats colorectal cancer and other gastrointestinal malignancies in adult patients. GNH USA supplies Oxaliplatin Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide.

GNH USA supplies Oxaliplatin Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving oncology centres worldwide.

Oxaliplatin Accord is used in the treatment of cancers that involve the gastrointestinal tract, targeting the disease pathway of DNA cross‑linking.

- Colorectal cancer: Enhances chemotherapy regimens to improve tumor response. - Gastric cancer: Used in combination protocols to increase treatment efficacy. - Pancreatic cancer: Contributes to multi‑drug regimens for advanced disease management.

Oxaliplatin may cause a range of adverse reactions, which vary in frequency and severity.

Common Side Effects: - Peripheral neuropathy: Tingling or numbness in the hands and feet. - Nausea and vomiting: Often mild to moderate in intensity. - Diarrhea: May occur during or after infusion. - Fatigue: Generalized tiredness experienced by many patients. - Elevated liver enzymes: Transient increase in hepatic function tests.

Serious or Rare Side Effects: - Severe neuropathy: Persistent or worsening sensory loss. - Hematologic toxicity: Neutropenia, anemia, or thrombocytopenia. - Allergic reactions: Rash, itching, or anaphylaxis. - Cardiac events: Arrhythmias or chest pain. - Renal impairment: Decreased kidney function observed in some cases.

When using Oxaliplatin Accord, clinicians should consider several safety measures to minimize risks.

- Renal function assessment: Evaluate baseline kidney function before initiating therapy. - Hepatic function monitoring: Check liver enzymes regularly during treatment. - Neuropathy surveillance: Conduct frequent neurological examinations to detect early signs. - Hematologic monitoring: Perform complete blood counts to identify cytopenias. - Drug interaction review: Assess concomitant medications for potential additive toxicity. - Store at ambient temperature: Keep in original packaging, protect from moisture and direct sunlight.

Oxaliplatin Accord can interact with other medications, requiring careful management.

Major Interactions (Avoid): - Nephrotoxic agents: Concurrent use with aminoglycosides may increase kidney damage. - Myelosuppressive chemotherapy: Combining with other bone‑marrow suppressing drugs can exacerbate cytopenias.

Moderate Interactions (Monitor Closely): - Antiemetics: Certain serotonin‑receptor antagonists may alter oxaliplatin pharmacokinetics. - Calcium‑based     - Calcium‑   \